These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 28964473)

  • 1. Immunosuppression in the pediatric transplant recipient.
    Blondet NM; Healey PJ; Hsu E
    Semin Pediatr Surg; 2017 Aug; 26(4):193-198. PubMed ID: 28964473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J
    Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in immunosuppression practices among pediatric liver transplant centers-Society of Pediatric Liver Transplantation survey results.
    Slowik V; Lerret SM; Lobritto SJ; Voulgarelis S; Vitola BE
    Pediatr Transplant; 2021 Mar; 25(2):e13873. PubMed ID: 33026158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eight-year follow-up in pediatric living donor kidney recipients receiving alemtuzumab induction.
    Kaabak MM; Babenko NN; Shapiro R; Maschan AA; Zokoev AK; Schekaturov SV; Vyunkova JN; Dymova OV
    Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28600850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving immunosuppressive regimens for lung transplant recipients.
    Meyer NJ; Bhorade SM
    Semin Respir Crit Care Med; 2006 Oct; 27(5):470-9. PubMed ID: 17072795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus for the prevention and treatment of rejection of solid organ transplants.
    Scalea JR; Levi ST; Ally W; Brayman KL
    Expert Rev Clin Immunol; 2016; 12(3):333-42. PubMed ID: 26588770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Controversies about the use of calcineurin inhibitors in pediatric patients].
    Dello Strologo L
    G Ital Nefrol; 2008; 25(3):317-24. PubMed ID: 18473303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Challenges of Tacrolimus for Maintenance Immunosuppression Post-Lung Transplantation.
    Ivulich S; Dooley M; Kirkpatrick C; Snell G
    Transplant Proc; 2017 Nov; 49(9):2153-2160. PubMed ID: 29149976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction immunosuppression for combined heart-lung transplantation.
    Hayes D; McConnell PI; Yates AR; Tobias JD; Galantowicz M; Mansour HM; Tumin D
    Clin Transplant; 2016 Oct; 30(10):1332-1339. PubMed ID: 27490992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
    Bond GJ; Mazariegos GV; Sindhi R; Abu-Elmagd KM; Reyes J
    J Pediatr Surg; 2005 Jan; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of immunosuppression in solid organ transplantation.
    Enderby C; Keller CA
    Am J Manag Care; 2015 Jan; 21(1 Suppl):s12-23. PubMed ID: 25734416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Modern immunosuppression after solid organ transplantation].
    Beimler J; Morath C; Zeier M
    Internist (Berl); 2014 Feb; 55(2):212-22. PubMed ID: 24518922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children.
    Pollock-Barziv SM; Finkelstein Y; Manlhiot C; Dipchand AI; Hebert D; Ng VL; Solomon M; McCrindle BW; Grant D
    Pediatr Transplant; 2010 Dec; 14(8):968-75. PubMed ID: 21040278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppression in uterus transplantation: from transplant to delivery.
    D'Amico G; Del Prete L; Eghtesad B; Hashimoto K; Miller C; Tzakis A; Quintini C; Falcone T
    Expert Opin Pharmacother; 2023 Jan; 24(1):29-35. PubMed ID: 35723045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent options in drug therapy after solid organ transplantation].
    Pőcze B; Németh P; Langer R
    Orv Hetil; 2012 Aug; 153(33):1294-301. PubMed ID: 22890176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New directions for induction immunosuppression strategy in solid organ transplantation.
    Hawksworth JS; Leeser D; Jindal RM; Falta E; Tadaki D; Elster EA
    Am J Surg; 2009 Apr; 197(4):515-24. PubMed ID: 19249743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
    Herzberg GZ; Rossi AF; Courtney M; Gelb BD
    J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.